id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3178-0009,FDA,FDA-2019-E-3178,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,,2024-12-18T17:03:33Z,,0,0,090000648687b92d
FDA-2019-E-3178-0008,FDA,FDA-2019-E-3178,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-10T05:00:00Z,2024,1,2024-01-10T05:00:00Z,,2024-01-10T19:50:54Z,,0,0,090000648638a338
FDA-2019-E-3178-0006,FDA,FDA-2019-E-3178,Determination of Regulatory Review Period for Purposes of Patent Extension; Omegaven,Notice,Determinations,2023-11-01T04:00:00Z,2023,11,2023-11-01T04:00:00Z,2024-01-03T04:59:59Z,2023-11-01T14:53:17Z,2023-24124,0,0,09000064861bdf63
FDA-2019-E-3178-0005,FDA,FDA-2019-E-3178,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-10-19T04:00:00Z,2023,10,2023-10-19T04:00:00Z,,2023-10-19T20:50:38Z,,0,0,090000648610f105
FDA-2019-E-3178-0004,FDA,FDA-2019-E-3178,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T21:25:59Z,,0,0,090000648555f87b
FDA-2019-E-3178-0003,FDA,FDA-2019-E-3178,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-02T05:00:00Z,2019,12,2019-12-02T05:00:00Z,,2019-12-02T18:27:30Z,,0,0,09000064841d9a6f
FDA-2019-E-3178-0002,FDA,FDA-2019-E-3178,Patent Extension Application from Greenberg Traurig LLP (on behalf of Children's Medical Center Corporation),Other,Application,2019-07-01T04:00:00Z,2019,7,2019-07-01T04:00:00Z,,2019-07-01T18:17:25Z,,0,0,0900006483d5421d
FDA-2019-E-3178-0001,FDA,FDA-2019-E-3178,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2019-07-01T04:00:00Z,2019,7,2019-07-01T04:00:00Z,,2019-07-01T18:12:16Z,,0,0,0900006483d5421c